Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.

doi:10.1007/s10637-015-0238-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.

Investigational new drugs - 1 Jun 2015

Rodrigues Heloisa Veasey, Ke Danxia, Lim JoAnn, Stephen Bettzy, Bellido Jorge, Janku Filip, Zinner Ralph, Tsimberidou Apostolia, Hong David, Piha-Paul Sarina, Fu Siqing, Naing Aung, Subbiah Vivek, Karp Daniel, Falchook Gerald, Kurzrock Razelle, Wheler Jennifer

Abstract excerpt

PURPOSE: Combining agents that block both the VEGF and PI3K/AKT/mTOR pathways may be synergistic. We explored a novel dosing schedule to assess safety, toxicity and activity in patients with advanced solid tumors. PATIENTS AND METHODS: Patients with refractory solid tumors were enrolled in a modified 3 + 3 Phase I dose escalation study to determine dose limiting toxicities (DLTs) and the maximum tolerated dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Everolimus

Share to Indazoles

Share to Neoplasm Staging

Share to Phosphatidylinositol 3-Kinases

Share to PTEN Phosphohydrolase

Share to Pyrimidines

Share to Sulfonamides

Source

Open in PubMed

Identifiers

PMID: 25902899
DOI: 10.1007/s10637-015-0238-2

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.PMID 25902899Read ↗

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.Semantic proximity Read ↗

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapySemantic proximity Read ↗

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsSemantic proximity Read ↗

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.Semantic proximity Read ↗

Antitumor Activity in <i>RAS</i> -Driven Tumors by Blocking AKT and MEKSemantic proximity Read ↗

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroidsSemantic proximity Read ↗

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.Semantic proximity Read ↗

A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway.Semantic proximity Read ↗

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.Semantic proximity Read ↗

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K.Semantic proximity Read ↗

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.